Ozempic Injection, Solution
Product Images NDC 50090-5949

Product Visual Gallery

This gallery contains 100 technical images submitted to the FDA as part of the official labeling for Ozempic (NDC 50090-5949). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ozempic_ifu_us_flow_symbol_1 (Export 00)

Ozempic 1.34 mg/mL injection, solution in a prefilled pen syringe displayed in the image. The label on the pen shows the product name, strength, dosage form, and the labeler A-S Medication Solutions. The pen is designed for subcutaneous use and includes dosage increment markings and a green cap on the needle end.*

FDA Label Image

Structural Formula (Image 01)

Chemical structure diagram of semaglutide, the active ingredient in Ozempic 1.34 mg/mL injection solution. The diagram shows the molecular structure with amino acid residues and chemical bonds typical for a peptide-based drug.*

FDA Label Image

Figure 1 (Image 02)

A line graph depicting plasma glucose levels (mg/dL) over 24 hours after a breakfast meal. The graph compares baseline and treated subjects using Ozempic (semaglutide) at 0.5 mg and 1 mg doses, and placebo groups, illustrating the glucose changes for each treatment group over time.*

FDA Label Image

Figure 2 (Image 03)

Line graph depicting insulin secretion rate (pmol/kg/min) as a function of plasma glucose levels (mg/dL) for different groups including CCEMPC baseline, CCEMPC 1 mg end of treatment, placebo end of treatment, placebo baseline, and healthy subjects. The graph shows comparative insulin secretion trends across these groups over the plasma glucose range from 90 to 210 mg/dL.*

FDA Label Image

Figure 3 (Image 04)

A forest plot chart showing relative exposure (Cavg) ratios and 90% confidence intervals for semaglutide by intrinsic factors including sex, age groups (65-74 years, >74 years), race (Black or African American, Asian), ethnicity (Hispanic or Latino), body weight (55 kg, 127 kg), and renal impairment levels (mild, moderate, severe). The graph compares exposure against a reference subject profile with average semaglutide concentration.*

FDA Label Image

Figure 4 (Image 05)

A forest plot chart showing relative exposure ratios and 90% confidence intervals for various co-administered medications with Ozempic (semaglutide). The medications listed include Metformin, S-warfarin, R-warfarin, Digoxin, Atorvastatin, Ethinylestradiol, and Levonorgestrel. All medications show a recommendation of no dose adjustment based on their exposure ratios near 1.0.*

FDA Label Image

Figure 5 (Image 06)

A line graph showing changes in HbA1c percentage over 56 weeks post randomization for three groups: Ozempic 0.5 mg, Ozempic 1 mg, and Sitagliptin. The graph includes sample size numbers at various time points and indicates observed mean HbA1c with dropout multiple imputation estimates, including standard error bars at week 56.*

FDA Label Image

Warning 1 (Image 07)

Ozempic 1.34 mg/mL injection solution for subcutaneous use in a pre-filled pen device. The label shows dosage strength and route, with packaging highlighting the product name, strength, and manufacturer A-S Medication Solutions.*

FDA Label Image

Device 1 (Image 08)

An instructional illustration showing the components and features of the Ozempic pen and NovoFine Plus needle. It labels parts such as the pen cap, pen window, dose counter, dose selector, dose button, and flow check symbol. Needle components including outer needle cap, inner needle cap, needle, and paper tab are also identified. The diagram notes the location of the expiration date and lot number on the pen label.*

FDA Label Image

A (Image 09)

An instructional illustration depicting a person using a pen-style injector. The image shows a hand gripping the device, positioned to remove or adjust a cap or cover, likely demonstrating preparation steps for subcutaneous injection.*

FDA Label Image

B (Image 10)

An instructional illustration showing a hand holding a syringe with the needle cap being removed, indicating preparation for injection.*

FDA Label Image

Flow_symbol (Image 100)

Ozempic 1.34 mg/mL injection solution label for subcutaneous use. The label shows the proprietary name Ozempic prominently, the active ingredient semaglutide, the dosage strength of 1.34 mg/mL, and the product type as a human prescription drug. Labeled by A-S Medication Solutions with NDC 50090-5949.*

FDA Label Image

Symbol (Image 101)

Ozempic 1.34 mg/mL injection solution, subcutaneous use, manufactured by A-S Medication Solutions. The label displays the product name, strength, dosage form, route, and labeler information clearly for this prescription drug.*

FDA Label Image

2 mg. Pen (Overview)

Illustration of the Ozempic pen and NovoFine Plus needle, showing labeled components including the pen cap, pen window, dose counter, dose pointer, dose selector, dose button, and needle parts such as outer and inner needle caps, needle, and paper tab. It also highlights the location of the expiration date on the pen label and the flow check symbol with a dashed line guide for dose setting.*

FDA Label Image

Step 1 (Fig. A)

An instructional illustration showing hands pulling or twisting a part of an injection device. The image likely demonstrates preparation or assembly steps for using a subcutaneous injection product.*

FDA Label Image

Step 1 (Fig. B)

An instructional illustration showing a close-up of a hand holding a prefilled pen injector. The pen is primarily light blue and white, depicting a step in the use of a subcutaneous injection device likely related to the Ozempic product.*

FDA Label Image

Step 1 (Fig. C)

An instructional illustration showing a hand pulling a cap off a needle or injection pen. The image includes a directional arrow indicating removal of the cap. It is likely part of usage instructions for an injection device.*

FDA Label Image

Step 1 (Fig. D)

An instructional illustration showing a person removing or securing the cap of a pen-style injection device, likely representing the preparation or use of Ozempic (semaglutide) injection, solution for subcutaneous administration.*

FDA Label Image

Step 1 (Fig. E)

An instructional illustration showing a hand gripping the cap of an injection pen and pulling it off, indicated by an arrow pointing away from the pen. The image demonstrates the step to remove the cap from the pen before use.*

FDA Label Image

C (Image 11)

An instructional illustration showing how to prepare a subcutaneous injection. It depicts a hand holding an injection device with an arrow indicating a push or pull action, likely demonstrating how to remove a cap or attach a needle before injection.*

FDA Label Image

Step 1 (Fig. F)

An instructional diagram showing a hand removing the cap from an Ozempic injection pen before use. The illustration depicts the correct step in preparing the semaglutide injection solution for subcutaneous administration.*

FDA Label Image

Step 2 (Fig. G)

An instructional illustration showing a flow check symbol being selected on a device, likely an Ozempic injection pen. The image depicts two hands holding the device with an arrow indicating the adjustment or activation of the flow check symbol for use confirmation.*

FDA Label Image

Step 2 (Fiig. H)

Illustration showing a hand holding a blue and transparent injection pen device for subcutaneous use, with the hand pressing the bottom part and an arrow pointing upward. A close-up of the top section of the pen device is inset in the upper right corner.*

FDA Label Image

Step 3 (Fig. I)

Instructional diagram showing a hand adjusting a dose selector on an injector pen dial. The image highlights the selection of a 2 mg dose, with an arrow indicating rotation to align the dashed line with the 2 mg mark, demonstrating dose setting for injection.*

FDA Label Image

Step 3 (Fig. J)

An instructional illustration showing a close-up of a hand holding an Ozempic injection pen, highlighting the dose counter window indicating a stopped dose with 2 mg left. The image includes text "Dose counter stopped: 2 mg left" explaining the dose status.*

FDA Label Image

Step 4 (Fig. K)

An instructional illustration showing the recommended subcutaneous injection sites on the human body. The diagram highlights areas on the abdomen and the front and outer sides of the thighs for injection placement.*

FDA Label Image

Step 4 (Fig. L)

Illustration showing a hand holding a pen-like injection device positioned vertically above a skin surface with a downward arrow indicating the direction of injection. The image likely demonstrates subcutaneous administration technique for an injection solution.*

FDA Label Image

Step 4 (Fig. M)

An instructional diagram showing the use of an injection pen in the subcutaneous route. It illustrates a hand holding the pen with an arrow indicating the direction to press down for injection, with a dose display window showing '0 mg.'*

FDA Label Image

Step 4 (Fig. N)

An instructional illustration showing a hand holding an injection pen. The image includes a speech bubble with the numbers 1 through 6, indicating the recommended counting pace for administering the injection slowly.*

FDA Label Image

Step 4 (Fig. O)

An instructional illustration showing a semaglutide injection pen held vertically with the needle cap being removed by pulling upward, indicated by an upward arrow. The background is light blue and the pen is shown in white and gray tones.*

FDA Label Image

D (Image 12)

An instructional illustration showing a hand holding a pen-like injection device, demonstrating how to prepare or use the injection. The device appears to be for subcutaneous administration, consistent with an injectable solution product like Ozempic (semaglutide).*

FDA Label Image

Step 5 (Fig. P)

An instructional illustration showing a hand twisting the cap of a prefilled injection pen, indicating the step to remove or unlock the cap. The image is part of usage instructions for an injectable medication device.*

FDA Label Image

Step 5 (Fig. Q)

An instructional diagram showing a step where a liquid is being poured from a small container into a larger container with segmented sections inside the opening, indicating a mixing or dosing step for a medication.*

FDA Label Image

Step 5 (Fig. R)

An instructional illustration showing hands manipulating a pen-style injection device. The right hand appears to be pulling the outer cap off the device, indicated by an arrow pointing upward. The device likely corresponds to a subcutaneous injection pen.*

FDA Label Image

Step 5 (Fig. S)

An instructional illustration showing how to attach a cap to a pen injector device. The image features two blue arrows indicating the direction for connecting the cap onto the pen, demonstrating proper assembly or closure.*

FDA Label Image

Warning Symbol (Image 124)

Ozempic 1.34 mg/mL injection solution for subcutaneous use in a prefilled pen. The label shows the A-S Medication Solutions name and other regulatory information. The product is identified by the NDC 50090-5949.*

FDA Label Image

Warning Symbol (Image 125)

The image shows the front label of Ozempic injection solution, with a strength of 1.34 mg/mL semaglutide, intended for subcutaneous use. The label includes the proprietary name Ozempic prominently, along with the labeler A-S Medication Solutions. It appears on a small vial container, suitable for prescription use.*

FDA Label Image

Warning Symbol (Image 126)

Ozempic 1.34 mg/mL injection, solution for subcutaneous use. The label shows the proprietary name Ozempic with the generic name semaglutide. The labeler is A-S Medication Solutions. The packaging includes usage instructions and a barcode with NDC 50090-5949.*

FDA Label Image

Dashed Line (Image 127)

Ozempic 1.34 mg/mL injection, solution for subcutaneous use in a pre-filled pen. The label shows the proprietary name Ozempic, generic name semaglutide, strength 1.34 mg/mL, and the labeler A-S Medication Solutions. Product NDC 50090-5949 is also displayed.*

FDA Label Image

Warning Symbol (Image 128)

Ozempic 1.34 mg/mL injection, solution in a single-use pre-filled pen cartridge. The label includes the product name, strength, dosage form, route (subcutaneous), and other regulatory information. The labeler is A-S Medication Solutions.*

FDA Label Image

Warning Symbol (Image 129)

The image shows the packaging label for Ozempic 1.34 mg/mL injection, solution for subcutaneous use. The label includes product name, concentration, dosage form, route, and states it is a prescription drug. The labeler is A-S Medication Solutions. Additional warnings and barcode are visible.*

FDA Label Image

E (Image 13)

An instructional diagram showing hands preparing an injection. One hand is holding a vial, and the other is attaching a needle to a syringe, illustrating the process of medication preparation for subcutaneous injection.*

FDA Label Image

Warning Symbol (Image 130)

Ozempic 1.34 mg/mL subcutaneous injection solution carton label. The label shows the product name, the active ingredient semaglutide, concentration, and the labeler A-S Medication Solutions. The carton includes storage instructions and a barcode area.*

FDA Label Image

Warning Symbol (Image 131)

Ozempic 1.34 mg/mL injection solution label for subcutaneous use from A-S Medication Solutions. The label shows prescribing and storage instructions with warnings listed, featuring detailed text panels and barcodes. It is designed for a single-dose pen injector device.*

FDA Label Image

Qr Code (Image 133)

FDA Label Image

F (Image 14)

An instructional illustration showing a close-up of a hand holding a vial or syringe with a needle being capped or uncapped. An arrow indicates the direction of movement for the needle cap. The image likely relates to preparation or administration of an injectable solution.*

FDA Label Image

Warning 2 (Image 15)

Ozempic 1.34 mg/mL injection, solution in a subcutaneous prefilled pen displayed with its packaging carton. The label and carton show the proprietary name Ozempic and generic name semaglutide, with the labeler noted as A-S Medication Solutions. The carton includes usage instructions and dosage information in text.*

FDA Label Image

Dose 1 (Image 16)

Ozempic 1.34 mg/mL injection, solution in a single-use prefilled pen. The label displays dosage form and strength with administration instructions. The labeler is A-S Medication Solutions, and the product NDC is 50090-5949.*

FDA Label Image

G (Image 17)

An instructional diagram showing a close-up view of an injection pen with a finger pressing a button. There is a flow check symbol visible near the pen's injection tip to indicate correct operation before use.*

FDA Label Image

H (Image 18)

Illustration showing the hands holding and preparing a semaglutide injection pen labeled as Ozempic 1.34 mg/mL. The image depicts the removal of the pen cap by pulling upwards, which is part of the injection preparation process for subcutaneous administration.*

FDA Label Image

Warning 3 (Image 19)

Ozempic 1.34 mg/mL injection solution in a subcutaneous prefilled pen syringe. The label shows the brand name Ozempic, the active ingredient semaglutide, strength 1.34 mg/mL, and directions for once weekly use. The labeler is A-S Medication Solutions.*

FDA Label Image

Dash 1 (Image 20)

Ozempic 1.34 mg/mL injection, solution, subcutaneous, single-dose pen cartridge packaging. The label includes the brand name Ozempic prominently, with the generic name semaglutide, and displays product information including strength and route of administration. The packaging is primarily white with purple and orange accents and shows the labeler as A-S Medication Solutions.*

FDA Label Image

I (Image 21)

An instructional illustration showing a close-up of a medication pen device. It highlights a display window with a dashed line indicating the selected dose of 1 mg. A finger is shown pulling a white cap off the pen, with an arrow pointing upward. The image guides the user on setting or confirming the dose selection on the pen for injection.*

FDA Label Image

Warning 4 (Image 22)

Ozempic 1.34 mg/mL injection solution in a subcutaneous prefilled pen syringe. The label shows dosage strength and route, with branding and labeling by A-S Medication Solutions. The image captures the pen syringe device used for administering the medication.*

FDA Label Image

J (Image 23)

An instructional illustration showing a close-up of a hand pressing the dose counter stopper on a pen injector for subcutaneous injection. The image highlights the area to achieve the setting of 1 mg left on the dose counter for the Ozempic (semaglutide) injection, solution 1.34 mg/mL.*

FDA Label Image

K (Image 24)

An instructional anatomical illustration showing front and back views of a human body. It highlights recommended subcutaneous injection sites for Ozempic (semaglutide) injection, solution, 1.34 mg/mL by A-S Medication Solutions.*

FDA Label Image

L (Image 25)

An instructional illustration showing a hand holding a pen-like injection device with an arrow pointing downward, likely indicating how to prepare or use the device for subcutaneous injection.*

FDA Label Image

M (Image 26)

An instructional diagram showing a hand holding an injection device with a downward arrow indicating the direction to press or inject. The illustration emphasizes the technique for administering a subcutaneous injection using the device.*

FDA Label Image

N (Image 27)

Illustration showing a hand holding an injection pen and a speech bubble with the text "Count slowly: 1-2-3-4-5-6," indicating instructions for counting during administration.*

FDA Label Image

O (Image 28)

An instructional diagram showing a close-up of a pen-style injection device with an arrow pointing upwards, suggesting the action of removing a cap or needle cover. The illustration is likely related to the preparation or administration of an injectable medication.*

FDA Label Image

Warning 5 (Image 29)

Ozempic 1.34 mg/mL injection, solution for subcutaneous use in a pen injector device. The label shows branding, dosage strength, and usage instructions for the single-dose pen. The labeler is A-S Medication Solutions. The NDC 50090-5949 is displayed on the packaging label.*

FDA Label Image

P (Image 30)

An instructional illustration depicting a hand removing or unlocking a cap from the top of a medication injection device, indicated by an arrow showing the direction to pull or twist the cap off. This image relates to proper preparation or assembly of the injection pen for subcutaneous use.*

FDA Label Image

Q (Image 31)

An instructional illustration showing a vial and a cap being removed or placed onto the vial, indicating how to open or close the vial cap before use.*

FDA Label Image

R (Image 32)

An instructional illustration showing a close-up of hands preparing a prefilled injection pen. One hand is holding the pen while the other hand is twisting the pen's cap, indicating the step to remove or attach the cap before injection.*

FDA Label Image

S (Image 33)

An instructional illustration showing how to attach or detach a device component, with arrows indicating the direction of movement. The image appears to demonstrate part of device assembly or use, related to the Ozempic injection solution.*

FDA Label Image

Warning 6 (Image 34)

Ozempic 1.34 mg/mL injection, solution for subcutaneous use in a 2 mL prefilled pen. The label includes the product name, strength, dosage form, the labeler A-S Medication Solutions, and usage instructions visible on the pen. This is a human prescription drug.*

FDA Label Image

Warning 7 (Image 35)

The image shows the packaging label for Ozempic 1.34 mg/mL solution injection. It includes the product name, semaglutide as the generic ingredient, subcutaneous route, and is labeled by A-S Medication Solutions. The label also contains dosage form and strength details, with a focus on the product's identity and usage information.*

FDA Label Image

Qr1 (Image 36)

FDA Label Image

Bull 1 (Image 37)

FDA Label Image

Warning 8 (Image 38)

Ozempic 1.34 mg/mL injection solution for subcutaneous use in a glass vial. The label shows the brand name Ozempic and the active ingredient semaglutide. Labeler A-S Medication Solutions is identified. The vial contains 1.34 mg/mL concentration and includes dosage and use instructions on the label.*

FDA Label Image

Device 2 (Image 39)

An instructional diagram showing parts of an Ozempic pen and NovoFine Plus needle, including the pen cap, pen window, dose counter, dose pointer, dose selector, dose button, outer needle cap, inner needle cap, needle, and paper tab. It also highlights the location for expiration date and lot number, plus symbols for flow check and dashed line for dose guidance.*

FDA Label Image

Figure A (Image 40)

An instructional illustration showing hands preparing a prefilled injection pen by attaching a needle. This image is related to the use of Ozempic (semaglutide) injection, solution, for subcutaneous administration.*

FDA Label Image

B (Image 41)

An instructional illustration showing a close-up of a hand holding a syringe or injection pen, indicating preparation or use of the device for subcutaneous injection. The image is simplified with blue and white colors, emphasizing the gripping and positioning of the injection device.*

FDA Label Image

C (Image 42)

An instructional diagram showing a close-up of hands preparing an injection pen, with one hand holding and the other manipulating a component, indicated by a black arrow pointing upwards.*

FDA Label Image

D (Image 43)

An instructional illustration showing a close-up of a hand holding an injection pen for subcutaneous administration. The image depicts the hand pressing or preparing the injection pen, likely demonstrating how to use the Ozempic (semaglutide) injection pen correctly.*

FDA Label Image

E (Image 44)

An instructional illustration showing a hand holding a syringe and a vial, demonstrating the process of removing a needle cap or preparing the injection. The image emphasizes safe handling of the injection equipment for subcutaneous administration.*

FDA Label Image

F (Image 45)

Instructional illustration showing a syringe being prepared for injection. The image depicts a hand holding a vial or pen device with an arrow indicating the removal of a cap or needle cover. This is part of the preparation process for subcutaneous injection.*

FDA Label Image

Warning 9 (Image 46)

Ozempic 1.34 mg/mL injection solution label for subcutaneous use from A-S Medication Solutions. The label is primarily white with purple text and includes the proprietary and generic names, strength, dosage form, and route. The labeler name and an NDC code (50090-5949) are also visible.*

FDA Label Image

Dose 2 (Image 47)

Ozempic 1.34 mg/mL injection solution in a subcutaneous prefilled pen syringe. The label includes branding, dosage strength, and usage instructions with visual step-by-step graphics on how to administer the injection. The labeler is A-S Medication Solutions. The packaging is designed for patient use with detailed administration guidance.*

FDA Label Image

G (Image 48)

An instructional illustration showing a finger pressing a button on a device's display panel, with a flow check symbol selected on the screen, likely demonstrating part of the usage instructions for an injection device.*

FDA Label Image

H (Image 49)

An instructional illustration showing a hand holding an injection pen device, identified as part of a subcutaneous injection administration process. The illustration features an arrow pointing upward, indicating the direction for preparing or using the injection pen, likely related to the Ozempic (semaglutide) injection. No text is visible besides the image details.*

FDA Label Image

Warning 10 (Image 50)

Ozempic 1.34 mg/mL injection, solution in a subcutaneous pen device. The label shows the product name, strength, dosage form, and route. The labeler is A-S Medication Solutions, and the product NDC is 50090-5949. The label also includes dosage instructions and usage information visible on the pen.*

FDA Label Image

Dash 2 (Image 51)

Ozempic 1.34 mg/mL injection, solution in a single-dose pen with a 3 mL capacity. The label shows the A-S Medication Solutions logo and states the product is for subcutaneous use only. Packaging includes lot number, expiration date, and storage information, with a red cap on the pen.*

FDA Label Image

I (Image 52)

An instructional diagram showing how to select the dose in a medication pen, specifically indicating the dialed line for a 0.25 mg dose and an example of a 0.5 mg dose.*

FDA Label Image

Warning 11 (Image 53)

Ozempic injection, solution in a prefilled pen, 1.34 mg/mL strength by A-S Medication Solutions. The label displays dosage form and strength clearly with brand and generic names. The background is white with blue and black text, showing the NDC 50090-5949 and instruction to read the package insert.*

FDA Label Image

J (Image 54)

An instructional illustration showing a hand holding a prefilled injection pen labeled 'Ozempic' with a dose counter displaying the number 2.5. The image demonstrates the correct method of preparing the pen for subcutaneous injection.*

FDA Label Image

K (Image 55)

An instructional illustration showing front and back views of a human torso with highlighted subcutaneous injection sites. The image indicates areas suitable for subcutaneous administration of medication, such as the abdomen and outer thighs.*

FDA Label Image

L (Image 56)

An instructional diagram showing a hand holding a pen-like injection device aimed at a skin fold on the abdomen. A downward arrow indicates the direction for injecting the solution subcutaneously, demonstrating proper injection technique for Ozempic (semaglutide) injection.*

FDA Label Image

M (Image 57)

An instructional diagram showing a right hand holding a pen-like injection device poised above a finger, illustrating the step of preparing or administering a subcutaneous injection with the device. The image includes an inset with a symbol resembling a small circle with a line, possibly indicating a device setting or component detail.*

FDA Label Image

N (Image 58)

An instructional illustration showing a hand holding a syringe-like injection pen with a speech bubble that reads, "Count slowly: 1-2-3-4-5-6." The image appears to guide users on timing or counting during injection.*

FDA Label Image

O (Image 59)

An instructional illustration showing a syringe with an arrow pointing upward, indicating the removal or attachment action of the needle or cap. The syringe is partially visible, and a curved surface is depicted below it, suggesting preparation or handling steps for injection.*

FDA Label Image

Warning 12 (Image 60)

Ozempic 1.34 mg/mL injection solution for subcutaneous use is shown in plain white packaging with prominent black text. The label includes the product's proprietary and generic names, concentration strength, administration route, and the labeler, A-S Medication Solutions, alongside NDC 50090-5949. The label is minimalistic with clear, legible text.*

FDA Label Image

P (Image 61)

An instructional illustration showing a hand opening the cap of a vial or pen by twisting it off as indicated by an arrow. The image is intended to demonstrate how to remove the cap from an injection vial or pen device for subcutaneous administration.*

FDA Label Image

Q (Image 62)

An instructional diagram showing a vial with a flip-off cap being removed by lifting it upward, demonstrating how to access the vial's rubber stopper for subcutaneous injection preparation.*

FDA Label Image

R (Image 63)

An instructional illustration showing a person holding a pen injector device with one hand and using the other hand to peel off or remove a protective cap or cover from the needle end of the injector. The image demonstrates the preparation step before a subcutaneous injection.*

FDA Label Image

S (Image 64)

An instructional diagram showing the assembly of an injection device, specifically depicting alignment of needle components for a subcutaneous injection. The illustration includes arrows indicating the connection points of the injection device parts, likely related to Ozempic (semaglutide) injection use.*

FDA Label Image

Warning 13 (Image 65)

Ozempic 1.34 mg/mL injection, solution for subcutaneous use supplied by A-S Medication Solutions. The label indicates it is a human prescription drug with the active ingredient semaglutide. The packaging shows a single-use pen injector device with branding and dosing information visible.*

FDA Label Image

Warning 14 (Image 66)

Ozempic 1.34 mg/mL injection, solution in a 1.5 mL multi-dose pen. The label features the brand name Ozempic prominently with dosage strength and prescribing information. It is labeled for subcutaneous use and manufactured by A-S Medication Solutions. The packaging includes detailed instructions and warnings printed on the pen container.*

FDA Label Image

Qr2 (Image 67)

FDA Label Image

Bull 2 (Image 68)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.